Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer

被引：0
|
作者：
Lee, Meng-Hsuan [1 ]
Hong, Shiao-Ya [2 ]
Kao, Yu-Rung [2 ]
Wu, Cheng-Wen [1 ]
机构：
[1] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan
[2] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4756
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
    Minatta, J. N.
    Deza, D.
    Aineseder, M.
    Nunez, M. Mestas
    Mosquera, C.
    Lupinacci, L.
    Benitez, S.
    Seehaus, A.
    Luna, D.
    Beresnak, A.
    Diaz, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1166 - S1166
  • [32] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    Oncology and Therapy, 2022, 10 : 13 - 22
  • [33] Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
    Namba, Kei
    Shien, Kazuhiko
    Takahashi, Yuta
    Torigoe, Hidejiro
    Sato, Hiroki
    Yoshioka, Takahiro
    Takeda, Tatsuaki
    Kurihara, Eisuke
    Ogoshi, Yusuke
    Yamamoto, Hiromasa
    Soh, Junichi
    Tomida, Shuta
    Toyooka, Shinichi
    MOLECULAR CANCER RESEARCH, 2019, 17 (02) : 499 - 507
  • [34] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [35] Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC)
    Zhao, Shen
    Zhao, Hongyun
    Zhang, Li
    Sun, Yuping
    Zhuang, Wu
    Dong, Xiaorong
    Zhou, Jianying
    Li, Mingjun
    Li, Xiaoyan
    Xi, Yuqin
    Zhang, Jintao
    Xu, Wen
    Li, Ao
    Chen, Qianrong
    Paradiso, Linda J.
    Myers, Thomas J.
    Zhang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhang, Qiu-Yi
    Ke, E-E
    Deng, Wei
    Niu, Fei-Yu
    Zhao, Ning
    Su, Jian
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
  • [37] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    CANCERS, 2019, 11 (07)
  • [38] Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer
    O'Byrne, K. J.
    Adams, M. N.
    Richard, D. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [39] Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
    Xu, Yingqi
    Ji, Hao
    Zhang, Yidan
    Xiong, Liwen
    Han, Baohui
    Zhong, Hua
    Xu, Jianlin
    Zhong, Runbo
    ONCOLOGIST, 2024, 29 (07): : e932 - e940
  • [40] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Tan, Aaron C.
    Teh, Yi Lin
    Lai, Gillianne G. Y.
    Tan, Daniel S. W.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
12345